Canada has long been recognized for its strength in scientific research. Across academic institutions and research centers, the country consistently produces high-impact discoveries that contribute to global advancements in medicine and biotechnology. However, translating that research into sustainable commercial success has historically been a challenge.
Building a thriving life sciences ecosystem requires more than scientific excellence. It depends on the ability to transform early-stage discoveries into viable companies, attract investment and scale innovation into globally competitive enterprises.
To explore how this transformation is taking place, Xtalks spoke with Gordon McCauley, Vice Chair and past President and CEO of adMare BioInnovations, an organization focused on company creation and early-stage investment in Canada’s life sciences sector. In the conversation, McCauley discussed adMare’s mission, the importance of domestic investment and what it will take to build a self-sustaining innovation ecosystem.
Translating Research into Scalable Companies
At the core of Canada’s life sciences challenge is a disconnect between strong research output and commercial development. While Canadian institutions generate world-class science, fewer of those discoveries are successfully translated into companies that grow and scale domestically.
adMare BioInnovations was created to address this gap.
“adMare is Canada’s company creation engine in the life sciences,” McCauley said.
The organization focuses on identifying promising research and supporting it through the earliest and riskiest stages of development. By working closely with researchers, universities and partners across the ecosystem, adMare helps transform scientific discoveries into investable opportunities.
“Our vision is Canadian life sciences leading the world,” McCauley explained.
This approach is rooted in the belief that Canada’s research strength can serve as the foundation for a globally competitive life sciences industry, if the right infrastructure and investment are in place.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Investing at the Earliest Stages of Drug Development
One of adMare’s distinguishing features is its focus on the pre-formation stage of company development, a phase often considered too risky for traditional investors.
The organization acts as an early-stage investor, supporting projects before they have reached the level of validation typically required to attract venture capital.
“We work with very early-stage companies, oftentimes at the critical pre-formation stages of companies,” McCauley said.
This work involves advancing early drug development, demonstrating proof of concept and building the foundation needed to attract additional funding. Once sufficient progress has been made, adMare helps lead company formation and brings in external investors.
The model has delivered measurable results.
To date, adMare’s team has helped create 39 companies, which have collectively attracted $2 billion in risk capital and are valued at more than $5 billion. These companies have also generated approximately 1,000 jobs.
“McCauley emphasized the organization’s track record in navigating this most challenging phase of development.
Beyond financial returns, this model is designed to build long-term capacity within Canada’s life sciences sector.
The Challenge of Domestic Venture Capital
Despite these successes, one of the most significant barriers to ecosystem growth remains the availability of domestic investment.
Canada invests heavily in basic research, with approximately $4.5 billion in public funding per year in 2024. However, much of the capital required to commercialize that research comes from outside the country.
In Canada, much of the life sciences venture capital comes from foreign investors, primarily from the United States, highlighting a significant gap in domestic funding.
This imbalance has important implications. When foreign investors provide the majority of funding, much of the economic value generated by Canadian innovation is captured outside the country.
McCauley argues that increasing domestic investment, particularly from institutional sources such as pension funds, is essential for retaining value within Canada and building a more self-sustaining ecosystem.
Importantly, he notes that this is not just a matter of national interest, but also of financial opportunity.
“The life sciences sector has been the single best-performing sector in venture capital over the course of the last 10 years,” McCauley said.
Balancing Company Creation and Policy Engagement
While adMare BioInnovations’ primary focus is company creation, the organization also plays an active role in broader ecosystem discussions.
The team engages with industry groups, policymakers and economic organizations to help shape the environment in which life sciences companies operate.
“We are pretty actively engaged in most of the public policy discussions,” McCauley said.
These efforts include participation in organizations such as BIOTECanada, Innovative Medicines Canada and the Canadian Chamber of Commerce, among others.
At the same time, McCauley emphasizes the importance of maintaining focus.
“At the end of the day, obviously our primary job is to create companies,” he said.
Balancing operational priorities with policy engagement allows adMare to contribute to systemic change while continuing to deliver on its core mission.
“When ecosystem challenges impede our ability to create companies, we ask ourselves what we can do to address them,” added McCauley.
To that end, in addition to helping fill the early-stage funding gap, adMare also provides more than 200,000 square feet of turnkey lab facilities and delivers industry-ready talent and executive leadership development programs to help Canadian life science companies scale and succeed. The organization also produces data-driven white papers that help to guide policy decisions.
Expanding Early-Stage Investment Opportunities
Looking ahead, one of adMare’s key priorities is increasing its capacity to support early-stage projects.
The organization’s existing portfolio is performing well, with several companies advancing more quickly than expected. While this is a positive outcome, it also requires significant capital investment, limiting the number of new projects that can be initiated.
“Our existing company portfolio is advancing quite nicely… better than we thought it would,” McCauley said.
To address this, adMare is seeking partnerships with public and private funding sources to expand its early-stage investment activities.
“We should be doing more in that area,” he noted.
Recent developments include the creation of new companies, such as Ocythera, and 26 Therapeutics.
By increasing investment at the earliest stages, adMare aims to strengthen the pipeline of future companies and support long-term ecosystem growth.
Building Anchor Companies for Long-Term Growth
A central theme in McCauley’s perspective on ecosystem development is the importance of anchor companies, large, successful organizations that serve as the foundation for broader industry growth.
“The only real objective of developing an ecosystem… is to build anchor companies,” he said.
Studies show that successful biotech ecosystems are typically anchored by a small number of large, high-growth companies that drive talent development, investment and continued company creation.
These companies play a critical role in creating a self-sustaining ecosystem. They generate talent, attract investment and provide the experience and infrastructure needed to support new ventures.
Canada has seen this dynamic before.
Historical examples such as BioChem Pharma in Montreal and QLT in Vancouver helped shape regional biotech ecosystems, with their influence continuing to be felt today.
“It’s still the case today that… there’s one, maybe two degrees of separation to QLT,” McCauley said, referring to the interconnected nature of talent within the industry.
More recent successes, including Bellus Health, demonstrate how these anchor companies can emerge from earlier generations of innovation.
By focusing on building and scaling such companies, the Canadian life sciences sector can move toward a more sustainable and globally competitive future.
The Future of Canada’s Life Sciences Ecosystem
Canada’s life sciences sector is at a crucial moment. Strong research foundations, growing industry collaboration and increasing investment activity, including increased Canadian defense investment, are creating new opportunities for growth.
However, realizing this potential will require continued focus on company creation, early-stage investment and the development of domestic capital sources.
For organizations like adMare BioInnovations, the goal is clear: to transform scientific excellence into economic and clinical impact.
As McCauley emphasized, building a thriving ecosystem is not the responsibility of any single organization, but a shared mission across the life sciences community.
“It’s what the Canadian ecosystem absolutely needs to do,” he said.
With the right combination of investment, collaboration and long-term vision, Canada has the opportunity to establish itself as a global leader in life sciences innovation.
Join or login to leave a comment
JOIN LOGIN